drugset / Trial / NCT06688058

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

NCT06688058

Phase 1 Active not recruiting 72 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialDouble-blindBasic science

Summary

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540D) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540D in healthy adults and if people tolerate it.

Timeline

Start
2024-12-20
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gardasil 9 Vaccine Intramuscular
Subject V540D Vaccine Intramuscular

Indications

No indication recorded.